StreetInsider.com News Articles

Form 8-K BIORA THERAPEUTICS, INC. For: Dec 27

Mon, 30 Dec 2024 08:07:00 -0500

si-local-file:///var/storage/secattach/20241230/24151130.html

Form 8-K BIORA THERAPEUTICS, INC. For: Dec 27

Mon, 30 Dec 2024 08:07:00 -0500

si-local-file:///var/storage/secattach/20241230/24151130.html

Form 4 BIORA THERAPEUTICS, INC. For: Dec 12 Filed by: Athyrium Opportunities Associates III LP

Mon, 16 Dec 2024 19:32:00 -0500

si-local-file:///var/storage/secattach/20241216/24111596.html

Form 4 BIORA THERAPEUTICS, INC. For: Dec 12 Filed by: Athyrium Opportunities Associates III LP

Mon, 16 Dec 2024 19:32:00 -0500

si-local-file:///var/storage/secattach/20241216/24111596.html

Form 8-K BIORA THERAPEUTICS, INC. For: Dec 10

Tue, 10 Dec 2024 07:00:00 -0500

si-local-file:///var/storage/secattach/20241210/24084917.html

Form 8-K BIORA THERAPEUTICS, INC. For: Dec 10

Tue, 10 Dec 2024 07:00:00 -0500

si-local-file:///var/storage/secattach/20241210/24084917.html

Biora Therapeutics (BIOR) PT Raised to $23 at H.C. Wainwright

Mon, 18 Nov 2024 06:56:53 -0500

(Updated - November 18, 2024 6:56 AM EST)

H.C. Wainwright analyst Joseph Pantginis raised the price target on Biora Therapeutics (NASDAQ: BIOR) to $23.00 (from $15.00) while maintaining a Buy rating.

The analyst commented: "Biora announced 3Q24 results on November 14, posting EPS of ($5.04) compared to our estimate of ($4.20) and consensus estimate of ($3.85). The company ended the quarter with approximately $3.2 million in cash. In 3Q24, Biora continued to advance its drug delivery device platforms. Important program updates, in our opinion, include: 1) NaviCap: During the quarter, Biora presented a summary of BT-600 Phase 1 clinical trial data at

Biora Therapeutics (BIOR) PT Raised to $23 at H.C. Wainwright

Mon, 18 Nov 2024 06:56:53 -0500

(Updated - November 18, 2024 6:56 AM EST)

H.C. Wainwright analyst Joseph Pantginis raised the price target on Biora Therapeutics (NASDAQ: BIOR) to $23.00 (from $15.00) while maintaining a Buy rating.

Form 8-K BIORA THERAPEUTICS, INC. For: Nov 13

Fri, 15 Nov 2024 16:05:00 -0500

si-local-file:///var/storage/secattach/20241115/23993098.html

Form 8-K BIORA THERAPEUTICS, INC. For: Nov 13

Fri, 15 Nov 2024 16:05:00 -0500

si-local-file:///var/storage/secattach/20241115/23993098.html

Biora Therapeutics (BIOR) Misses Q3 EPS by 504c

Thu, 14 Nov 2024 17:13:19 -0500

Biora Therapeutics (NASDAQ: BIOR) reported Q3 EPS of ($5.04). Revenue for the quarter came in at $30 thousand.

For earnings history and earnings-related data on Biora Therapeutics (BIOR) click here.

Form 10-Q BIORA THERAPEUTICS, INC. For: Sep 30

Thu, 14 Nov 2024 16:12:00 -0500

si-local-file:///var/storage/secattach/20241114/23986031.html

Form 10-Q BIORA THERAPEUTICS, INC. For: Sep 30

Thu, 14 Nov 2024 16:12:00 -0500

si-local-file:///var/storage/secattach/20241114/23986031.html

Form 8-K BIORA THERAPEUTICS, INC. For: Nov 14

Thu, 14 Nov 2024 16:06:00 -0500

si-local-file:///var/storage/secattach/20241114/23985610.html

Form 8-K BIORA THERAPEUTICS, INC. For: Nov 14

Thu, 14 Nov 2024 16:06:00 -0500

si-local-file:///var/storage/secattach/20241114/23985610.html

Form SC 13G BIORA THERAPEUTICS, INC. Filed by: HIGHBRIDGE CAPITAL MANAGEMENT LLC

Thu, 14 Nov 2024 10:01:00 -0500

si-local-file:///var/storage/secattach/20241114/23980940.html

Form SC 13G BIORA THERAPEUTICS, INC. Filed by: HIGHBRIDGE CAPITAL MANAGEMENT LLC

Thu, 14 Nov 2024 10:01:00 -0500

si-local-file:///var/storage/secattach/20241114/23980940.html

Biora Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results

Thu, 14 Nov 2024 08:00:00 -0500

Testing in advanced animal model planned in Q4 for smaller, 00-size BioJet device with largest capacity of any ingestible injectable

Company granted extension until December 9 to regain compliance with Nasdaq listing requirements for market value of securities

SAN DIEGO, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company reimagining therapeutic delivery, today provided a corporate update and reported financial results for the third quarter ended September 30, 2024. The company will not host a conference call.

“We’ve made much faster progress than anticipated developing a smaller BioJet device

Biora Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results

Thu, 14 Nov 2024 08:00:00 -0500

Testing in advanced animal model planned in Q4 for smaller, 00-size BioJet device with largest capacity of any ingestible injectable

Company granted extension until December 9 to regain compliance with Nasdaq listing requirements for market value of securities

“We’ve made much faster progress than anticipated developing a smaller BioJet device

Biora Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update

Thu, 07 Nov 2024 16:30:00 -0500

SAN DIEGO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company reimagining therapeutic delivery, today announced it will report financial results and provide a corporate update for the third quarter ended September 30, 2024. Company management will host a webcast and conference call on Thursday, November 14, 2024, after the close of financial markets.

Conference Call and Webcast Information

Date:

Conference Call and Webcast Information
Date: